Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000031563
JPRN-UMIN000031563
Not yet recruiting
未知

Effect of canagliflozin as an alternative drug from DPP-4 inhibitor on heart failure with diabetis melltus : the pilot study "Can canagliflozin HAve Not only hypoGlycemic but cardiac supportive Effect?" - CHANGE trial

Osaka Rosai Hospital0 sites40 target enrollmentMarch 4, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionschronic heart failure with type 2 diabetis mellitus

Overview

Phase
未知
Intervention
Not specified
Conditions
chronic heart failure with type 2 diabetis mellitus
Sponsor
Osaka Rosai Hospital
Enrollment
40
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 4, 2018
End Date
December 31, 2020
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\. End stage renal failure including eGFR\<15ml/min/1\.73m2 or dialytic therapy 2\. Treated with SGLT2 inhibitor 3\. Contraindications of SGLT2 inhibitor 4\. Type 1 diabetes mellitus 5\. The pregnant, breast feeder 6\. BMI\<18\.5kg/m2

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Study of the beneficial effect of Canagliflozin on nocturnal home BP in Japanese T2DM patients(SHIFT-J STUDY)Type 2 diabetes mellitus patients with hypertension
JPRN-UMIN000023487Jichi Medical University School of Medicine100
Completed
Phase 4
A clinical trial to compare the effects of Canagliflozin and Sitagliptin in Patients with Type 2 Diabetes mellitus on a background metformin therapy.Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases
CTRI/2019/02/017435SRM College of Pharmacy40
Recruiting
Not Applicable
The efficacy and safety of Canagliflozin for the treatment of NAFLD/NASH patients with type2 DMAFLD/NASH
JPRN-UMIN000036560ippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology30
Completed
Not Applicable
The efficacy and safety in canaglifrozin therapy for diabetes complicated by non-alcoholic fatty liver disease.onalcoholic fatty liver disease type 2 diabetes mellitus
JPRN-UMIN000023044Kyoto prefetural University of Medicine20
Completed
Not Applicable
The effect of canagliflozin on the blood sugar levels of people without diabetes after weight loss surgeryHypoglycaemia after eating due to weight-loss surgerySurgery
ISRCTN11342830niversity of Leicester36